The MedTech Edge: July 2026 Edition

Strategies, regulatory intel, and expert guidance across the full lifecycle of MedTech innovation: concept to commercialization. ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏

View in browser

From manufacturing readiness to evidence strategy, this month’s newsletter is focused on one theme: better planning leads to better outcomes. Inside, you’ll find practical updates on development, regulatory readiness, clinical site selection, biocompatibility, and expert-led blog insights on the challenges that can shape product success regarding regulatory pathways and histology insights.

This Month's Service Spotlights

Introducing EFS Explorer

A Smarter Way to Identify Early Feasibility Study Sites

Finding the right clinical sites early can make all the difference in an Early Feasibility Study (EFS). That's why Veranex, in collaboration with MDIC, is proud to introduce EFS Explorer. This new online platform combines publicly available ClinicalTrials.gov data with curated insights to help sponsors quickly identify experienced research sites, evaluate relevant study history, and make more informed site selection decisions.

Industry Insights From Our Experts

BtX Is Rolling Out. Be Ready to Take Advantage.

It's not a shortcut, but a more supportive framework enabling earlier interaction and structured planning.

Preclinical Results Point to a New Chapter for the Heart Valve.

Non-degenerative, non-calcifying, and no longer theoretical. New Foldax TAVR technology may be the answer.

Challenging Assumptions Mitigates Risk: Battle Test the Real Use Environment

Five devices, five environments nobody tested. Here's what use environment assumptions cost when they're wrong.

**What Your Manufacturing Contract Doesn't Say Could Cost You the Most.**

Indemnification, change control, hidden equipment costs. The fine print decides who pays when something goes wrong.

Three Preclinical Studies That Died at Necropsy, Not in the Lab.

Tissue discarded. Samples insufficient. A polymer device that dissolved mid-processing. All preventable, and all fatal to the timeline.

What If The Pathologist Who Reads Your Slides Also Helped Design the Study?

No handoff, no cold read, no report written by someone seeing the tissue for the first time. That continuity is the whole advantage.

Product Design & Engineering
Preclinical & Pathology | Clinical Research (CRO)

Regulatory Quality | Commercialization